Skip To Content

Study ID: COG ANHL12P1

Title:

A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117

Location:
Sioux Falls Region
Principal Investigator:
Kayelyn Wagner, MD
Disease:
NHL (Non-Hodgkins Lymphoma)
Stage:
Phase II
Status:
Active - Partially Closed to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.